2015 American Transplant Congress
Patient and Graft Outcomes Following 3rd, 4th and 5th Renal Transplants – A Single Centre Comparative Study
Guy's and St Thomas' Hospital - NHS Foundation Trust, London, United Kingdom.
Introduction: For patients who have lost their first renal graft, a second kidney transplant is widely accepted as the next best therapeutic option (due to…2015 American Transplant Congress
Reasons for Match Offer Refusals and Efforts to Reduce Them in the OPTN/UNOS Kidney Paired Donation Pilot Program (KPDPP)
1UNOS, Richmond, VA; 2Carnegie Mellon Univ, Pittsburgh, PA; 3Univ Hosp Case Med Ctr, Cleveland, OH.
Background: The OPTN/UNOS KPDPP has been finding 2-way, 3-way, and chain exchanges since Oct 2010. Though the number of pairs entered, matches found, and transplants…2015 American Transplant Congress
Belatacept-Treated Patients Had Better Graft Survival at 7-Years Post-Transplant Compared With Cyclosporine-Treated Patients: Final Results from BENEFIT
Background: At 3yrs, improvement in renal function was seen in kidney transplant recipients treated with belatacept (bela) vs cyclosporine (CsA) in BENEFIT. Here we report…2015 American Transplant Congress
Plasmapheresis – A Previously Unrecognised Risk Factor for BK Viraemia
BK nephropathy is an important preventable cause of graft loss, with the only universally accepted risk factor being overall burden of immunosuppression. In the absence…2015 American Transplant Congress
Recurrent IgA Nephropathy in Kidney Transplant Recipients Receiving a Steroid Sparing Immunosuppression Protocol
Background: Steroid sparing immunosuppression is increasingly used in order to avoid the many well-known side effects of steroids. It has been argued that steroid use…2015 American Transplant Congress
Outcomes of Eculizumab (ANTI-C5) Therapy for Treatment of Refractory Antiobdy-Mediated Rejection (ABMR) and Thrombotic Microangiopathy (TMA)
Introduction: ABMR results from DSA binding to donor endothelium initiating the classical complement pathway. This results in the formation of terminal MAC (C5b-C9) complex and…2015 American Transplant Congress
Cyclophosphamide as a Salvage Therapy for Combined Intravenous Immunoglobulins and Plasmapheresis Refractory Antibody-Mediated Rejection
Acute antibody-mediated rejection (AMR) poses a significant risk to graft survival. Current or standard treatment (ST) of AMR currently consists of plasmapheresis (PP), intravenous immunoglobulin…2015 American Transplant Congress
IL-17 Production Influenced by Induction Therapy With ATG
Introduction Immune-mediated rejection remains the most important cause of graft failure. Recently, a newly identified CD4+ T cell subset, Th17, distinct from Th1 or Th2,…2015 American Transplant Congress
Diabetes Mellitus and Prediabetes On Kidney Transplant Waiting List – Prevalence, Metabolic Phenotyping and Risk Stratification Approach
Purpose: Diabetes mellitus (DM), the most common cause of ESRD, limits access to transplantation and impairs patient and allograft outcome. Prediabetes is an independent risk…2015 American Transplant Congress
Burden of Early Antibody-Mediated Rejection (AMR): Complications, Resource Utilization and Cost-Differential in Treatment of AMR
Early antibody-mediated rejection (AMR) is common in positive crossmatch kidney transplants (+XMKTx). The current study determined the complications, resource utilization and cost associated with early,…
- « Previous Page
- 1
- …
- 523
- 524
- 525
- 526
- 527
- …
- 531
- Next Page »